Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612002 | 0.89 | ATM (0.51) | L3MBTL1CA2CA1 | |
| SCHEMBL27695345 | 0.88 | ALDH1A1 (0.50) | L3MBTL1KDM4AMMEGPR132 | |
| SCHEMBL1612910 | 0.86 | L3MBTL1 (0.69) | L3MBTL1CA2CA1PTPN1NAALAD2 | |
| SCHEMBL28611563 | 0.81 | CTSD (0.56) | L3MBTL1CA2CA1KDM4APTPN1 | |
| SCHEMBL13555269 | 0.76 | KDM4A (0.49) | L3MBTL1KDM4AITGA4MMEKMT2A | |
| SCHEMBL4001531 | 0.75 | L3MBTL1 (0.57) | L3MBTL1CA2CA1PTPN1NAALAD2 | |
| SCHEMBL9489744 | 0.75 | L3MBTL1 (0.57) | L3MBTL1CA2CA1PTPN1NAALAD2 | |
| SCHEMBL4001530 | 0.75 | L3MBTL1 (0.57) | L3MBTL1CA2CA1PTPN1NAALAD2 | |
| SCHEMBL15145381 | 0.74 | L3MBTL1 (0.71) | L3MBTL1CA2CA1PTPN1NAALAD2 | |
| SCHEMBL7442014 | 0.74 | CA2 (0.74) | CA2CA1PTPN1ACEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| CN-101044137-A | 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-09-26 | — | — | CN | disclosed |
| EP-1781640-A1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006021544-A1 | 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.